Biota is a leading anti-infective drug development company based in MelbourneAustralia, with key expertise in respiratory diseases, particularly influenza.  Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza.  Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections.  Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.

In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir®, is approved for marketing in Japan.

Relenza™ is a registered trademark of the GlaxoSmithKline group of companies.
Biota Holdings Limited (ASX:BTA)
Company Directors
Mr Damian Lismore (CFO, Investor Relations)
Mr Grant F Latta, B.Bus, MBA,CPA (Non Exec. Director)
DR. Ian D Gust, MD, MBS, BSc, DipBact, FRCPA, MASM, FTS (Non Exec. Director)
DR. James Fox (Chairman, Non Exec. Director)
Prof. Jeffrey Errington, FRS RMedSci (Non Exec. Director)
Mr Paul R Bell, BA, MA Hons (Non Exec. Director)
Mr Peter Cook (Managing Director, CEO)
Mr Richard James Hill, B.A, LL.B, LL.M (Non Exec. Director)
Contact Information
Phone: +61 3 9915 3700
Email:
Website:

Address
10/585 Blackburn Road, NOTTING HILL, VIC, AUSTRALIA, 3168
Media Releases
Latest Company News
  • Market Wrap: ASX slumps 2.4%
    16 May 2012 - ASX slumps 2.4%. BHP Billiton Limited (ASX:BHP) chief executive Marius Kloppers says most miners will face lower cash flows because of higher costs, lower commodity prices and slower gro...read more
  • Biota announce proposed US merger
    23 Apr 2012 - Biota Holdings Limited (ASX:BTA) has inked a deal with US company Nabi Biopharmaceuticals.
  • Midday: Aus shares gain 0.5%
    24 Jan 2012 - Aus shares gain 0.5%. Investment firm Milton Corporation Limited (ASX:MLT) increases its half year net profit by 19 per cent and dividend by 2.7 per cent.
  • Market Wrap: Aus shares start week 1% down
    27 Jun 2011 - Aus shares start week 1% down. Engineering company UGL Ltd (ASX:UGL) secures $400 million in new resource contracts from companies such as BHP Billiton Ltd (ASX:BHP), Rio Tinto Ltd’s (AS...read more
  • Midday: Energy stocks drive local gains
    01 Apr 2011 - Energy stocks drive local gains. Gunns Ltd (ASX:GNS) will suspend its Tasmanian Triabunna woodchip operations because of the impact of the Japanese earthquake and strengthening Australia...read more
  • Biota awarded $231M US contract
    01 Apr 2011 - Biota Holdings Ltd (ASX:BTA) is awarded a $231 million contract from the US Department of Health and Human Services to develop influenza antiviral Laninamivir.